SEARCH

SEARCH BY CITATION

References

  • 1
    Potts GO, Creange JE, Hardong HR, et al. Trilostane, an orally active inhibitor of steroid biosynthesis. Steroids 1978;32:257267.
  • 2
    Neiger R, Ramsey I, O'Connor J, et al. Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism. Vet Rec 2002;150:799804.
  • 3
    Ruckstuhl NS, Nett CS, Reusch CE. Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Am J Vet Res 2002;63:506512.
  • 4
    Wenger M, Sieber-Ruckstuhl NS, Muller C, et al. Effect of trilostane on serum concentrations of aldosterone, cortisol, and potassium in dogs with pituitary-dependent hyperadrenocorticism. Am J Vet Res 2004;65:12451250.
  • 5
    Bell R, Neiger R, McGrotty Y, et al. Study of the effects of once daily doses of trilostane on cortisol concentrations and responsiveness to adrenocorticotropic hormone in hyperadrenocorticoid dogs. Vet Rec 2006;159:277281.
  • 6
    Witt AL, Neiger R. Adrenocorticotropic hormone levels in dogs with pituitary-dependent hyperadrenocorticism following trilostane therapy. Vet Rec 2004;154:399400.
  • 7
    Sieber-Ruckstuhl NS, Boretti MS, Wenger M, et al. Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependant hyperadrenocorticism treated with trilostane. Domest Anim Endocrinol 2006;31:6375.
  • 8
    Galac S, Buijtels JJCWM, Mol JA, Kooistra HA. Effects of trilostane treatment on the pituitary-adrenocortical and renin-aldosterone axis in dogs with pituitary-dependent hypercortisolism. Vet J 2008, doi:DOI: 10.1016/j.tvjl.208.10.007.
  • 9
    Peterson ME. Containing costs of ACTH-stimulation test. J Am Vet Med Assoc 2004;224:198199.
  • 10
    Rijnberk A, Van Wees A, Mol JA. Assessment of two tests for the diagnosis of canine hyperadrenocorticism. Vet Rec 1988;122:178180.
  • 11
    Meij BP, Voorhout G, Rijnberk A. Progress in transsphenoidal hypophysectomy for treatment of pituitary-dependent hyperadrenocorticism in dogs and cats. Mol Cell Endocrinol 2002;197:8996.
  • 12
    Den Hertog E, Braakman JCA, Teske E, et al. Results of non-selective adrenocorticolysis by o,p′-DDD in 129 dogs with pituitary-dependent hyperadrenocorticism. Vet Rec 1999;144:1217.
  • 13
    Frank LA, Davis JA, Oliver JW. Serum concentrations of cortisol, sex hormones of adrenal origin, and adrenocortical steroid intermediates in healthy dogs following stimulation with two doses of cosyntropin. Am J Vet Res 2004;65:16311633.
  • 14
    Stolp R, Rijnberk A, Meijer JC, et al. Urinary corticoids in the diagnosis of canine hyperadrenocorticism. Res Vet Sci 1983;34:141144.
  • 15
    Van Vonderen IK, Kooistra HS, Rijnberk A. Influence of veterinary care on the urinary corticoid: Creatinine ratio in dogs. J Vet Int Med 1998;12:431435.
  • 16
    Rijnberk A. Adrenals. In: RijnberkA, ed. Clinical Endocrinology of Dogs and Cats. Dordrecht, the Netherlands: Kluwer Academic Publishers; 1996:6193.
  • 17
    Galac S, Kooistra HS, Teske E, Rijnberk A. Urinary corticoid/creatinine ratio in the differentiation between pituitary-dependent hyperadrenocorticism and hyperadrenocorticism due to adrenocortical tumor in the dog. Vet Q 1997;19:1720.
  • 18
    Javadi S, Galac S, Boer P, et al. Aldosterone to renin ratio and cortisol to adrenocorticotropic hormone ratio in healthy dogs and dogs with primary hypoadrenocorticism. J Vet Int Med 2006;20:556561.
  • 19
    Randolph JF, Toomey J, Center SA, et al. Use of the urine cortisol-to-creatinine ratio for monitoring dogs with pituitary-dependent hyperadrenocorticism during induction treatment with mitotane. Am J Vet Res 1998;59:258261.
  • 20
    Angles JM, Feldman EC, Nelson RW, Feldman MS. Use of urine cortisol:creatinine ratio versus adrenocorticotropic hormone stimulation testing for monitoring mitotane treatment of pituitary-dependent hyperadrenocorticism in dogs. J Am Vet Med Assoc 1997;15:10021004.
  • 21
    Komanicky P, Spark RF, Melby JC. Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis. J Clin Endocrinol Metab 1978;47:10421051.
  • 22
    Gröndal S, Erikson B, Hagenas L, et al. Steroid profile in urine: A useful tool in the diagnosis and follow up of adrenocortical carcinoma. Acta Endocrinol (Copenh) 1990;122:656663.
  • 23
    Kikuchi E, Yanaihara H, Nakashima J, et al. Urinary steroid profile in adrenocortical tumors. Biomed Pharmacother 2000;54:194197.
  • 24
    Russcher H, Smit P, Van Rossum EF, et al. Strategies for the characterization of disorders in cortisol sensitivity. J Clin Endocrinol Metab 2006;91:694701.
  • 25
    Vermeer H, Hendriks-Stegeman BI, Van Suylekom D, et al. An in vitro bioassay to determine individual sensitivity to glucocorticoids: Induction of FKBP51 mRNA in peripheral blood mononuclear cells. Mol Cell Endocrinol 2004;218:4955.
  • 26
    Chapman PS, Kelly DF, Archer J, et al. Adrenal necrosis in a dog receiving trilostane for the treatment of hyperadrenocorticism. J Small Anim Pract 2004;45:307310.
  • 27
    Ramsey IK, Richardson J, Lenard Z, et al. Persistent isolated hypocortisolism following brief treatment with trilostane. Aust Vet J 2008;86:491499.
  • 28
    Reusch CE, Sieber-Ruckstuhl N, Wenger M, et al. Histological evaluation of the adrenal glands of seven dogs with hyperadrenocorticism treated with trilostane. Vet Rec 2007;160:219224.